Biocon Limited — Q2FY27 earnings call summary

Filed 11 November 2026 · Official transcript

Interest costs down 12% y-y to INR240 Cr; expected to decline further; depreciation stable
$400m 10-year Pertuzumab contract in Brazil starts Q4FY27; strong biosimilars growth expected in H2FY27
Pertuzumab global settlement enables launches from early 2027 in EU/UK, Q3 2028 in US
Insulin franchise growing >$300m annual run rate; new capacity commissioned in Malaysia
Biosimilars revenue INR2809 Cr; EBITDA INR623 Cr; H1 margin 24%; logistics delays deferred ~5% revenue to Q3
Generics revenue INR774 Cr; EBITDA INR64 Cr; margin improved to 8% from 1% y-y; H1 grew 15% y-y
Services revenue INR833 Cr; EBITDA INR175 Cr; margin improved to 20% from 15% q-o-q
Q2FY27 group operating revenues grew 2% y-y; biosimilars up 5%, services up 13% q-q